In JoVE (1)
Other Publications (1)
Articles by Marc Carceles-Cordon in JoVE
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel Lisa Mohr1, Marc Carceles-Cordon1, Jungreem Woo1, Carlos Cordon-Cardo1, Josep Domingo-Domenech1, Veronica Rodriguez-Bravo1,2 1Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 2Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Resistance to cancer therapies contributes to disease progression and death. Determining the mechanistic underpinnings of resistance is crucial for improving therapeutic response. This manuscript details the protocol to generate taxane-resistant cell models of prostate cancer (PC) to help dissecting the pathways involved in progression to Docetaxel resistance in PC patients.
Other articles by Marc Carceles-Cordon on PubMed
The Role of GATA2 in Lethal Prostate Cancer Aggressiveness Nature Reviews. Urology. Jan, 2017 | Pubmed ID: 27872477 Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.